TIAA CREF Investment Management LLC Has $4.48 Million Position in CytomX Therapeutics (CTMX)

TIAA CREF Investment Management LLC reduced its position in shares of CytomX Therapeutics (NASDAQ:CTMX) by 10.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 212,047 shares of the biotechnology company’s stock after selling 25,652 shares during the period. TIAA CREF Investment Management LLC’s holdings in CytomX Therapeutics were worth $4,476,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CTMX. New York State Common Retirement Fund raised its holdings in CytomX Therapeutics by 18.6% during the third quarter. New York State Common Retirement Fund now owns 36,900 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 5,800 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in CytomX Therapeutics by 11.6% during the third quarter. Bank of New York Mellon Corp now owns 129,182 shares of the biotechnology company’s stock worth $2,347,000 after purchasing an additional 13,405 shares in the last quarter. Macquarie Group Ltd. purchased a new position in CytomX Therapeutics during the third quarter worth about $107,000. Wells Fargo & Company MN raised its holdings in CytomX Therapeutics by 47.3% during the third quarter. Wells Fargo & Company MN now owns 60,739 shares of the biotechnology company’s stock worth $1,104,000 after purchasing an additional 19,506 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its holdings in CytomX Therapeutics by 43.0% during the third quarter. Schwab Charles Investment Management Inc. now owns 168,223 shares of the biotechnology company’s stock worth $3,057,000 after purchasing an additional 50,581 shares in the last quarter. 78.07% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

A number of brokerages have issued reports on CTMX. BidaskClub cut shares of CytomX Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, March 30th. Zacks Investment Research cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, February 19th. Bank of America increased their target price on shares of CytomX Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, March 8th. Citigroup began coverage on shares of CytomX Therapeutics in a report on Friday, January 5th. They issued a “buy” rating and a $40.00 target price for the company. Finally, ValuEngine raised shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $37.86.

In other news, insider Rachel Humphrey sold 23,840 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $30.00, for a total value of $715,200.00. Following the sale, the insider now directly owns 54,074 shares in the company, valued at $1,622,220. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Debanjan Ray sold 2,548 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $26.69, for a total transaction of $68,006.12. Following the completion of the sale, the chief financial officer now owns 4,741 shares in the company, valued at $126,537.29. The disclosure for this sale can be found here. Insiders sold 103,548 shares of company stock worth $3,101,686 over the last quarter. Company insiders own 4.70% of the company’s stock.

Shares of CytomX Therapeutics stock opened at $27.01 on Friday. CytomX Therapeutics has a 12-month low of $13.00 and a 12-month high of $35.00.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Wednesday, March 7th. The biotechnology company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.43) by $0.45. The business had revenue of $27.07 million for the quarter, compared to analyst estimates of $10.70 million. CytomX Therapeutics had a negative net margin of 60.17% and a negative return on equity of 71.42%. sell-side analysts expect that CytomX Therapeutics will post -1.44 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/21/tiaa-cref-investment-management-llc-has-4-48-million-position-in-cytomx-therapeutics-ctmx.html.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply